▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #2938 by analyst upside · 2026-06-27
OMDA
Omada Health, Inc.
Healthcare · Market Cap $1B · P/E 0x
ANALYST PRICE TARGET
+9.7%
implied upside to consensus target
Current Price $20.89
Consensus Target $22.92
Bull Target $30.0
Bear Target $15.0
Analysts Covering 12
ANALYST CONSENSUS - BUY
Strong Buy
4
Buy
5
Hold
2
Sell
1
52-Week Low $10.28
52-Week High $26.91
YTD Return +40.2%
FUNDAMENTALS
Market Cap $1B
P/E Ratio (TTM) N/A
Forward P/E 43.8x
EPS (TTM) $-0.23
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $283M
Profit Margin -2.2%
52-WEEK RANGE
52-Week Low $10.28
52-Week High $26.91
Current Price $20.89
Bear Target $15.0
Bull Target $30.0
● Now $20.89 ● Target $22.92
TRADING DATA
Avg Volume 1.0M
YTD Return +40.2%
Analyst Count 12
Consensus Buy
Upside to Target +9.7%
Last Updated 2026-06-27

ANALYST SUMMARY

Omada Health, Inc. (OMDA) is currently trading at $20.89 with a Wall Street consensus price target of $22.92, implying potential upside of 9.7% over the next 12 months. 12 analysts currently cover OMDA, with a consensus rating of Buy - 75% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $30.0, while the most cautious has a target of $15.0.

OMDA operates in the Healthcare sector with a market capitalisation of $1B. The stock is up 40.2% year-to-date and is currently trading near the upper end of its 52-week range of $10.28 – $26.91.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

INSP +11.4%
Inspire Medical Systems, Inc.
$1B · P/E 9.9x · Hold
CNMD +10.2%
CONMED Corporation
$1B · P/E 19.5x · Hold
ARDT +27.5%
Ardent Health, Inc.
$1B · P/E 10.4x · Buy
AMPH +4.8%
Amphastar Pharmaceuticals, Inc.
$960M · P/E 13.1x · Buy
ABUS +10.7%
Arbutus Biopharma Corporation
$905M · P/E 5.5x · Strong Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for OMDA, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Barclays — Reiterated
Overweight → Overweight 2026-05-08 Building track record
Citizens — Reiterated
Market Outperform → Market Outperform 2026-05-08 Building track record
Evercore ISI Group — Reiterated
Outperform → Outperform 2026-05-08 Building track record
Wells Fargo — Reiterated
Equal-Weight → Equal-Weight 2026-05-08 Building track record
Needham reit
Buy → Buy 2026-05-08 20% win rate (5 calls)
Citizens ● Initiated
Market Outperform 2026-04-14 Building track record
Goldman Sachs — Reiterated
Buy → Buy 2026-04-09 Building track record
Evercore ISI Group — Reiterated
Outperform → Outperform 2026-04-08 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
50
out of 100
Coverage depth
20/30
Consensus clarity
16/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →